Abstract-Based on observational studies, there is a linear increase in cardiovascular risk with higher systolic blood pressure (SBP), yet clinical trials have not shown benefit across all SBP categories. We assessed whether troponin T measured using high-sensitivity assay was associated with cardiovascular disease within SBP categories in 11 191 Atherosclerosis Risk in Communities study participants. Rested sitting SBP by 10-mm Hg increments and troponin categories were identified. Incident heart failure hospitalization, coronary heart disease, and stroke were ascertained for a median of 12 years after excluding individuals with corresponding disease. Approximately 53% of each type of cardiovascular event occurred in individuals with SBP<140 mm Hg and troponin T ≥3 ng/L. Higher troponin T was associated with increasing cardiovascular events across most SBP categories. The association was strongest for heart failure and least strong for stroke. There was no similar association of SBP with cardiovascular events across troponin T categories. Individuals with troponin T ≥3 ng/L and SBP <140 mm Hg had higher cardiovascular risk compared with those with troponin T <3 ng/L and SBP 140 to 159 mm Hg. Higher troponin T levels within narrow SBP categories portend increased cardiovascular risk, particularly for heart failure. Individuals with lower SBP but measurable troponin T had greater cardiovascular risk compared with those with suboptimal SBP but undetectable troponin T. Future trials of systolic hypertension may benefit by using high-sensitivity troponin T to target high-risk patients. (Hypertension. 2015;65:00-00.) • Online Data Supplement
levated blood pressure (BP) is a modifiable risk factor strongly associated with coronary heart disease (CHD), stroke, and heart failure (HF). 1, 2 Observational studies have shown that beginning at a BP of 115/75 mm Hg, the risk for cardiovascular disease doubles with each 20/10-mm Hg increment in BP. 3 Similarly, the presence of hypertension classifies an individual as having stage A HF (ie, at increased risk for future development of HF). 4 Clinical trials have generally shown that BP reduction in individuals with hypertension resulted in decreased cardiovascular disease incidence, including HF. 5 Although BP-lowering interventions are clearly associated with improved outcomes at systolic BP (SBP) >150 mm Hg, recent studies evaluating intensive control of BP have shown no benefit. 2 For example, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, SBP reduction in diabetics to <120 mm Hg did not lower cardiovascular events when compared with lowering SBP to <140 mm Hg. 6 In fact, the 2014 report from the Panel Members Appointed to the Eighth Joint National Committee has revised the BP management targets in hypertension such that for individuals aged ≥60 years, therapy is now advocated only for SBP ≥150 mm Hg or diastolic BP ≥90 mm Hg. 2 Epidemiological studies, on the contrary, have shown a monotonic, linear increase in cardiovascular risk with increasing SBP starting at 115 mm Hg. 3 This disconnect between epidemiological studies and clinical trial results suggests that the risk associated with intensive antihypertensive treatment negates the potential benefit of lower BP when Hypertension was defined as SBP ≥140 mm Hg, diastolic BP ≥90 mm Hg, or use of antihypertensive medications. We used the following prespecified categories of SBP for our analysis: <120, 120 to 129, 130 to 139, 140 to 149, 150 to 159, and ≥160 mm Hg.
The specific details about the cTnT assay have been previously published. 9 Briefly, cTnT concentrations were measured with a highsensitivity assay, Elecsys Troponin T (Roche Diagnostics), on an automated Cobas e411 analyzer with a lower limit of measurement of 3 ng/L. Similar to our previous analyses, we used 5 prespecified categories of cTnT (<3, 3-5, 6-8, 9-13, and ≥14 ng/L). 9 
Ascertainment of Incident Cardiovascular Events
All potential cardiovascular events were adjudicated based on published criteria. 16, 17 Incident CHD was defined as hospitalization for myocardial infarction, definite coronary death, coronary revascularization procedure, or silent myocardial infarction as confirmed by ECG. Hard CHD events excluded coronary revascularization procedures. Stroke was defined as sudden or rapid onset of neurological symptoms lasting for >24 hours or leading to death, in the absence of evidence for a nonstroke cause. 16 Incident HF was defined as the first HF hospitalization identified with International Classification of Diseases Code of 428 (Ninth Revision) or I50 (Tenth Revision) in any position on the hospital discharge list or a death certificate with death from HF in any position. 18 
Statistical Analysis
Our main outcomes of interest were incident CHD (total or hard CHD), stroke (all types), and first HF hospitalization. All presented tests were 2 tailed, and a P value <0.05 was considered statistically significant. Using Cox proportional hazards model, the associations between categories of cTnT or SBP and incident events were assessed using a model adjusted for age, race, sex, antihypertensive medication use, log of N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, diabetes mellitus, fasting glucose, total/ high-density lipoprotein cholesterol ratio, body mass index, current cigarette smoking, and cardiovascular disease status. Follow-up time ended when the participant had an outcome, died, was lost to followup, or survived until December 31, 2009.
We used 2 reference groups in our main analysis: (1) cTnT <3 ng/L and SBP <120 mm Hg and (2) cTnT <3 ng/L and SBP 140 to 159 mm Hg. The second reference group was used to examine whether individuals with measurable cTnT at levels of SBP where therapy will not be required currently had increased cardiovascular risk compared with those with higher SBP but cTnT below the lower limit of measurement. We performed the following sensitivity analyses: adjusted the model further for LVH as determined by ECG; used each SBP category and cTnT <3 ng/L as a reference; used cTnT ≤5 ng/L as a reference because cTnT of 5 ng/L is considered the limit of detection; and modeled cTnT as a continuous variable by keeping the same categories of SBP. Finally, using 2 different references in separate analyses (SBP <120 mm Hg and cTnT <3 ng/L; SBP 140-159 mm Hg and cTnT<3 ng/L), we performed subgroup analyses by the status of antihypertensive medication use.
Results

Baseline Characteristics
The mean age of the study population was 63 years (SD, 6), and ≈22% were blacks and 56% were women ( Table 1 ). The mean BP (Table S1 ). Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, sex, antihypertensive medication use, log N-terminal pro-B-type natriuretic peptide, renal function (estimated glomerular filtration rate), diabetes mellitus status, fasting glucose, total cholesterol/ high-density lipoprotein cholesterol ratio, body mass index, current cigarette smoking, and previous cardiovascular disease status (except the outcome for each model; eg, for heart failure, we adjusted for coronary heart disease and stroke). CHD indicates coronary heart disease.
Numbers in parentheses indicate number of participants. Reference group: systolic blood pressure <120 mm Hg and troponin T <3 ng/L. P for trend was calculated based on the results of Wald χ 2 test on linearity hypothesis of ordered high-sensitivity cardiac troponin T (cTnT) or systolic blood pressure (SBP) categories.
*P for trend across rows (ie, trend across increasing cTnT at each SBP category). †P for trend across columns (ie, trend across increasing SBP at each cTnT category). Figure) . The association with HF was strong, with significant associations starting even at lower levels of cTnT across most SBP categories. There were similar but attenuated associations for CHD and hard CHD ( Figure S2A and S2B) and further weaker association for stroke, particularly at lower SBP categories ( Figure S2C ). Compared with individuals with SBP <120 mm Hg and cTnT <3 ng/L, those with SBP 130 to 139 mm Hg and cTnT ≥14 ng/L had hazard ratios of 4.1 (95% confidence interval [CI], 2.6-6.4) for incident HF hospitalization; 2.0 (95% CI, 1.3-2.9) for CHD; 1.8 (95% CI, 1.1-2.9) for hard CHD; and 1.9 (95% CI, 1.0-3.6) for stroke ( Table 2 ). In contrast, the trend and the strength of associations of increasing SBP with each cardiovascular event across each cTnT category were not as robust (Table 2) .
When the reference was changed to SBP 140 to 159 mm Hg and cTnT <3 ng/L, there were similar trends for cardiovascular events (Table 3) with individuals with cTnT ≥3 ng/L (especially those with higher cTnT ranges) having significantly increased hazards for cardiovascular events. For example, individuals with SBP 130 to 139 mm Hg and cTnT ≥14 ng/L had hazard ratios of 3.7 (95% CI, 2.3-6.1) for incident HF hospitalization, 1.7 (95% CI, 1.1-2.6) for CHD, 2.2 (95% CI, 1.2-4.0) for hard CHD, and 1.8 (95% CI, 0.9-3.7) for stroke.
In additional analyses, similar results were obtained when the model was further adjusted for ECG-diagnosed LVH (Table S2 ) or when the reference was changed to each SBP category and cTnT <3 ng/L (data not presented). We obtained similar results when cTnT ≤5 ng/L replaced cTnT <3 ng/L (Table S3) . When cTnT was modeled as a continuous variable, there were significant hazards for HF, CHD, and hard CHD across each category of SBP per 1-SD increase in cTnT (17 ng/L; Table S4 ). Results were less robust for stroke. Finally, when we analyzed the hazards for the different end points stratified by the use of antihypertensive medications, the results were for the most part consistent with the primary analysis whether we used SBP <120 mm Hg and cTnT <3 ng/L or SBP 140 to 159 and cTnT <3 ng/L as the reference (Tables S5A, S5D , S6A, and S6D), except for CHD outcomes (Tables S5B, S5C , S6B, and S6C).
Discussion
In these analyses, we show that individuals with higher levels of cTnT have significantly increased risk for incident cardiovascular events within narrow SBP categories, with the strongest hazards observed in individuals with the highest cTnT levels in each SBP category. The association was particularly strong for HF. Although the association between cTnT and various cardiovascular events has been previously described in several studies, 10, 12 including the ARIC study, 9, 11 the value of measuring cTnT as a marker of the effect of BP on incident cardiovascular outcomes has not been previously reported. In a study of 176 Japanese hypertensive individuals free of cardiovascular disease, troponin T ≥20 ng/L was independently associated with hospitalization for cardiovascular or cerebrovascular disease (hazard ratio, 6.58; P<0.0001) compared with 39 normal controls 19 ; however, this study did not use the high-sensitivity assay. Because cTnT is a marker of myocardial injury (an important step in the pathophysiology of adverse cardiovascular events, such as HF), we hypothesized that cTnT assessment would identify those individuals in whom risk factors, such as hypertension, have a particularly adverse impact and render them at higher risk for incident cardiovascular events. Indeed, one of the most important findings of our study was that among individuals with SBP who will not require therapy per current US guidelines 2 (eg, <140 mm Hg), those with increased cTnT levels had significantly higher hazards for cardiovascular events when compared with those with suboptimal SBP (eg, SBP 140-159 mm Hg) but cTnT below the lower limit of measurement ( Table 3) .
The association with stroke was not as robust, particularly at lower BP categories, likely related to the smaller number of individuals with incident stroke and perhaps also is a reflection of other important pathophysiological mechanisms of stroke. On the contrary, increase in SBP within each cTnT category was not generally associated with a significant trend for increasing risk for incident cardiovascular events ( Table 2 ). This suggests that the effect of SBP was attenuated once we accounted for cTnT, indicating that myocardial injury may mediate the effects of SBP on HF and, to a lesser extent, on other cardiovascular end points. Therefore, cTnT may serve as a sensitive surrogate to identify individuals with elevated BP who have subclinical cardiac end-organ injury and, hence, are at greater risk for incident cardiovascular disease, especially HF. If replicated, such an observation has important clinical and research implications.
Elevated BP is a well-established risk factor for cardiovascular disease, and interventions that lower BP have generally decreased cardiovascular events. 5 This benefit has not been uniformly observed across all the BP and age ranges. The authors of the 2014 US guidelines for management of hypertension concluded that although there is a strong evidence to initiate pharmacological treatment for individuals with BP ≥150/90 mm Hg, the same level of evidence was not present at lower SBPs. 2 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended a goal BP of <130/80 mm Hg in individuals with diabetes mellitus and chronic kidney disease as an attempt to identify highrisk groups who would likely derive the most benefit from intensive BP treatment.
1 Although specific to diabetics, the ACCORD trial failed to show that intensive lowering of SBP (a mean of 119.3 mm Hg was achieved) was superior to traditional management of SBP (a mean SBP of 133.5 mm Hg was achieved in the placebo arm) among diabetics. 6 Similarly, a lower BP goal (eg, <130/80 mm Hg) did not significantly lower renal or cardiovascular end points in patients with chronic kidney disease. 2 On the contrary, a meta-analysis of epidemiological studies showed that the risk for cardiovascular disease doubles with each 20/10 mm Hg increase in BP, beginning at BP of 115/75 mm Hg, 3 whereas another meta-analysis documented an increased risk of stroke in a dose-response manner as BP increased from (120-129)/(80-84) to (130-139)/(85-89) mm Hg. 20 Therefore, the literature reflects a clear disconnect between epidemiological studies and clinical trials, viz, the benefits of BP reduction at different BP levels. A deeper understanding of the circumstances under which the risk of the intervention exceeds the benefit of BP lowering as benchmarked against the population at large is needed. Identifying susceptible individuals, for instance, those further advanced in the pathophysiological cascade of adverse cardiovascular events, may help optimize the risk to benefit balance and provide opportunities to personalize the management of elevated BP. Indeed, a recent meta-analysis of clinical trials of antihypertensive medications showed that as the baseline cardiovascular risk increased there was progressively greater absolute risk reductions in major cardiovascular events. Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, sex, antihypertensive medication use, log N-terminal pro-B-type natriuretic peptide, renal function (estimated glomerular filtration rate), diabetes mellitus status, fasting glucose, total cholesterol/ high-density lipoprotein cholesterol ratio, body mass index, current cigarette smoking, and previous cardiovascular disease status (except the outcome for each model; eg, for heart failure, we adjusted for coronary heart disease and stroke). CHD indicates coronary heart disease.
Numbers of participants in each group are the same as in Table 2 . Reference group: systolic blood pressure 140 to159 mm Hg and troponin T <3 ng/L. by guest on June 6, 2017 http://hyper.ahajournals.org/
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Troponin T is a sensitive marker of myocardial injury, 8 which is likely an important contribution in the pathogenesis of adverse cardiovascular events, such as HF. This study found that ≈53% of each type of cardiovascular event occurred in individuals with SBP <140 mm Hg and cTnT ≥3 ng/L. Taken together with other data, such as that from the Dallas Heart Study where measurable cTnT (≥3 ng/L) was associated with further increased hazards for adverse cardiovascular events among individuals with LVH, 14 we think that future clinical trials can benefit from the use of cTnT to help characterize susceptible individuals in whom therapy options can be tested to personalize the management of elevate BP and the prevention of its sequelae.
The strengths of our study include a well-characterized large biracial population (majority women) followed up for a median of 12 years with careful adjudication of incident cardiovascular events. There were some limitations as well. Some individuals with measurable cTnT and low SBP (eg, <140 mm Hg) could possibly have had subclinical left ventricular dysfunction, which could not be evaluated because of lack of echocardiography data. All individuals in our analysis were asymptomatic and hence, echocardiogram would not have been clinically recommended. 21 Hence, despite our inability to evaluate for subclinical left ventricular dysfunction clinically, our results will still have significant value. Furthermore, because the ARIC study conducts ongoing and comprehensive surveillance for cardiovascular-related hospitalizations and outcomes of its cohort, 22 it is less likely that individuals with significant left ventricular dysfunction, who would most likely be symptomatic, would have been missed. In addition, one may expect the use of BP-lowering medications, such as angiotensin-converting enzyme inhibitors in these individuals, but our subgroup analyses stratified by antihypertensive medication use showed results similar to that of the overall population for most end points and SBP categories. We further showed that cTnT remains associated with cardiovascular events independent of N-terminal pro-B-type natriuretic peptide and other cardiovascular risk factors. The original ARIC cohort was selected based on random sampling of participants. It is possible that visit 4 participants were a healthier subcohort of the original sample. However, if the association is strong in a healthier population (as we report), then it is likely that the association would have persisted with a sicker population as well. Finally, the observational design of our study also requires that our results be interpreted with caution, particularly in contrast to the information emerging from clinical trials that have the benefit of randomization. Although prospective and rigorously standardized, as well as analyzed with inclusion of pertinent covariates, residual confounding cannot be ruled out.
Perspectives
cTnT is strongly associated with cardiovascular events across all SBP categories, including prehypertensives. By perhaps identifying individuals with subclinical myocardial injury, cTnT may help identify the individuals most compromised in their pathophysiology, and thus most prone to incident cardiovascular events. Future clinical trials should consider cTnT as a marker to identify subjects at higher risk for cardiovascular events in whom aggressive risk factor modification can be tested.
Sources of Funding
The Atherosclerosis Risk in Communities Study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN2682011 00009C, HHSN268201100010C, HHSN268201100011C, and HHSN 268201100012C). What Is New?
Disclosures
• High-sensitivity troponin T is associated with increased adverse cardiovascular events across the range of systolic blood pressure within 10 mm Hg systolic blood pressure increments.
What Is Relevant?
• The risk for incident adverse cardiovascular end points of individuals with cardiovascular risk factors, such as systolic blood pressure, can be better characterized by measuring a marker of myocardial injury (troponin T). Such approaches may contribute to personalize the delivery of care in individuals with elevated blood pressure by identifying those further advanced in the pathophysiological cascade toward incident cardiovascular events.
Online Supplemental Methods
Population
The ARIC study is a prospective population-based study of 15,792 participants from 4 U.S. communities who were between the ages of 45 and 64 years in [1987] [1988] [1989] . Detailed information about the study design, objectives and sampling strategy has been previously described 1 . The 4 th ARIC visit (1996-1998) formed the baseline for this analysis; cTnT was measured in 2010 on blood samples collected during this visit. The 99th percentile value for cTnT measured by this assay was 30 ng/L in the entire ARIC population and was 27 ng/L in participants without CV disease 2 Similarly N terminal pro-Btype natriuretic peptide (NT-pro BNP) was measured on blood samples from visit 4.
A total of 11,656 participants attended ARIC visit 4; of these, 465 individuals were excluded for the following reasons: race other than African American or white (n=31), African American participants from the Minnesota or Washington field centers (n=37), missing cTnT data (n=395) and missing BP data (n=2) thereby leaving 11, 191 participants for our analysis (Supplemental Figure 1) . The African American participants from the Minnesota or
Washington field centers were excluded as their numbers were small and not thought to adequately represent these communities.
Diabetes was defined as fasting blood glucose level ≥126 mg/dL, non-fasting blood glucose level ≥200 mg/dL, or self-reported physician diagnosis of or treatment for diabetes. Total cholesterol and high-density lipoprotein cholesterol 
Statistical analysis
The variables included in our model were selected based on clinical judgment and results from the literature. Proportional hazards assumption was confirmed using time-dependent covariates and likelihood ratio statistics. All analyses were performed using SAS version 9. Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, gender, antihypertensive medication use, log NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total cholesterol/HDL-C ratio, BMI, current cigarette smoking, electrocardiogram diagnosed LVH and previous CV disease status (except the outcome for each model; e.g., for HF, we adjusted for CHD and stroke).
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12 BMI = body mass index, CHD = coronary heart disease, cTnT = high-sensitivity cardiac troponin T, CV = cardiovascular, HDL-C = high-density lipoprotein cholesterol, HF = heart failure, NT-proBNP = N-terminal pro-B-type natriuretic peptide, SBP = systolic blood pressure Numbers in parentheses indicate number of participants.
P for trend was calculated based on the results of Wald chi-square test on linearity hypothesis of ordered cTnT or SBP categories.
* P for trend across rows (i.e., trend across increasing cTnT at each SBP category) † P for trend across columns (i.e., trend across increasing SBP at each cTnT category) Table S3 . Incident hazard rate ratios of cardiovascular outcomes in the study population across systolic blood pressure and troponin-T categories (reference group: systolic blood pressure <120 mmHg and troponin T ≤5 ng/L) SBP (mmHg) [n] cTnT (ng/L) [ 1.3-3.3 Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, gender, antihypertensive medication use, log NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total cholesterol/HDL-C ratio, BMI, current cigarette smoking and previous CV disease status (except the outcome for each model; e.g., for HF, we adjusted for CHD and stroke). BMI = body mass index, CHD = coronary heart disease, cTnT = high-sensitivity cardiac troponin-T, CV = cardiovascular, HDL-C = high-density lipoprotein cholesterol, HF = heart failure, NT-pro BNP = N-terminal pro-B-type natriuretic peptide, SBP = systolic blood pressure HYPE201404206-R1
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Numbers in parentheses indicate number of participants.
* P for trend across rows (i.e., trend across increasing cTnT at each SBP category) † P for trend across columns (i.e., trend across increasing SBP at each cTnT category) NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total cholesterol/HDL-C ratio, BMI, current cigarette smoking and previous CV disease status (except the outcome for each model; e.g., for HF, we adjusted for CHD and stroke). BMI = body mass index, CHD = coronary heart disease, cTnT = high-sensitivity cardiac troponin-T, CV = cardiovascular, HDL-C = high-density lipoprotein cholesterol, HF = heart failure, NT-proBNP = N-terminal pro-B-type natriuretic peptide, SBP = systolic blood pressure
HYPE201404206-R1
18 Table S5 A-D. Incident hazard rate ratios of cardiovascular outcomes in the whole study population and by the status of antihypertensive medication use across systolic blood pressure and troponin T categories (reference group: systolic blood pressure <120 mmHg and troponin-T <3 ng/L) -Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, gender, antihypertensive medication use, log NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total cholesterol/HDL-C ratio, BMI, current cigarette smoking and previous CV disease status (except the outcome for each model; e.g., for HF, we adjusted for CHD and stroke).
In each SBP category, the first row [all] shows data for the overall study participants; second and third rows [no and yes]
show data for individuals who were not or were on antihypertensive medication respectively. BMI = body mass index, CHD = coronary heart disease, cTnT = high-sensitivity cardiac troponin-T, CV = cardiovascular, HDL-C = high-density lipoprotein cholesterol, HF = heart failure, NT-proBNP = N-terminal pro-B-type natriuretic peptide, SBP = systolic blood pressure Numbers in parentheses indicate number of participants.
P-trend was calculated based on the results of Wald chi-square test on linearity hypothesis of ordered cTnT categories. Stroke was defined as both ischemic and non-ischemic stroke.
23 Table S6 A-D. Incident hazard rate ratios of cardiovascular outcomes in the whole study population and by the status of antihypertensive medication use across systolic blood pressure and troponin T categories (reference group: systolic blood pressure 140-159 mmHg and troponin-T <3 ng/L) -Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, gender, antihypertensive medication use, log NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total cholesterol/HDL-C ratio, BMI, current cigarette smoking and previous CV disease status (except the outcome for each model; e.g., for HF, we adjusted for CHD and stroke).
In each SBP category, the first row [all] shows data for the overall study participants; second and third rows [no and yes] show data for individuals who were not or were on antihypertensive medication respectively. BMI = body mass index, CHD = coronary heart disease, cTnT = high-sensitivity cardiac troponin-T, CV = cardiovascular, HDL-C = high-density lipoprotein cholesterol, HF = heart failure, NT-proBNP = N-terminal pro-B-type natriuretic peptide, SBP = systolic blood pressure Numbers in parentheses indicate number of participants.
P-trend was calculated based on the results of Wald chi-square test on linearity hypothesis of ordered cTnT categories. Hard coronary heart disease excluded coronary revascularization.
27 The figures show hazards for cardiovascular events by systolic blood pressure and high-sensitivity cardiac troponin-T. The data is based on a model adjusted for age, race, gender, antihypertensive medication use, NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total cholesterol/high-density lipoprotein cholesterol ratio, body mass index, current cigarette smoking and previous cardiovascular disease status (except the outcome for each model; e.g., for heart failure, we adjusted for coronary heart disease and stroke). 
